middle.news
Rhythm Biosciences Launches ColoSTAT® Commercialisation, Secures NHS England Partnership
9:44am on Friday 23rd of January, 2026 AEDT
•
Healthcare
Read Story
Rhythm Biosciences Launches ColoSTAT® Commercialisation, Secures NHS England Partnership
9:44am on Friday 23rd of January, 2026 AEDT
Key Points
ColoSTAT® commercialisation launched with ISO 15189 – 2022 accreditation
NHS England to independently evaluate ColoSTAT®, validating global potential
geneType™ platform expanded with new US partnerships and enhanced colorectal cancer risk test
Harvard Medical School publishes validation of geneType™ ovarian cancer risk model
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
RHYTHM BIOSCIENCES (ASX:RHY)
OPEN ARTICLE